Tobias Volker Lanz

This study shows CD19-CAR T-cell therapy depletes EBV+ autoreactive B cells and resets their repertoire, leading to sustained remission, while rituximab does not.

This paper develops TGF-β agonists targeting specific T and B cells to selectively suppress pathogenic immune responses in autoimmune and inflammatory diseases.

The paper shows EBV infects and reprograms autoreactive B cells into antigen-presenting cells in MS, driving pathogenic T cell responses.

This study identifies senescent activated naive B cells in ACPA+ individuals that promote anti-citrullinated antigen T cell responses and drive progression to clinical RA.

This paper introduces modulADAR, a modular RNA sensor that enables detection of short RNA subsequences by leveraging ADARs' editing capabilities, overcoming limitations of previous sequence-dependent sensors.